{"title":"Role of claudin-6 in high-grade endometrial carcinoma: Implications for risk stratification and personalized treatment strategies.","authors":"Chuang Cai, Jin-Man Chen, Zu-Xun Qiu, Shu-Qi Ren","doi":"10.5306/wjco.v17.i2.116390","DOIUrl":null,"url":null,"abstract":"<p><p>This commentary discusses the groundbreaking study by Ebrahim <i>et al</i> on the role of claudin-6 (CLDN6) in high-grade endometrial carcinoma, addressing a significant gap in current knowledge. Their research reveals that overexpression of CLDN6 is linked to unfavorable pathological features. Moreover, multivariate analysis establishes CLDN6 as an independent predictor of disease-free survival, with a hazard ratio of 68.98. These results highlight the promise of CLDN6 in improving risk stratification and as a potential therapeutic target, especially with the development of CLDN6-directed antibody-drug conjugates. To advance CLDN6 towards clinical application, further validation in prospective patient cohorts and studies exploring its interactions with other molecular pathways are essential.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"17 2","pages":"116390"},"PeriodicalIF":3.2000,"publicationDate":"2026-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12968531/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5306/wjco.v17.i2.116390","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
This commentary discusses the groundbreaking study by Ebrahim et al on the role of claudin-6 (CLDN6) in high-grade endometrial carcinoma, addressing a significant gap in current knowledge. Their research reveals that overexpression of CLDN6 is linked to unfavorable pathological features. Moreover, multivariate analysis establishes CLDN6 as an independent predictor of disease-free survival, with a hazard ratio of 68.98. These results highlight the promise of CLDN6 in improving risk stratification and as a potential therapeutic target, especially with the development of CLDN6-directed antibody-drug conjugates. To advance CLDN6 towards clinical application, further validation in prospective patient cohorts and studies exploring its interactions with other molecular pathways are essential.
期刊介绍：
The WJCO is a high-quality, peer reviewed, open-access journal. The primary task of WJCO is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of oncology. In order to promote productive academic communication, the peer review process for the WJCO is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCO are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in oncology. Scope: Art of Oncology, Biology of Neoplasia, Breast Cancer, Cancer Prevention and Control, Cancer-Related Complications, Diagnosis in Oncology, Gastrointestinal Cancer, Genetic Testing For Cancer, Gynecologic Cancer, Head and Neck Cancer, Hematologic Malignancy, Lung Cancer, Melanoma, Molecular Oncology, Neurooncology, Palliative and Supportive Care, Pediatric Oncology, Surgical Oncology, Translational Oncology, and Urologic Oncology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
